Back to search results

Exercise for Prostate Cancer on Active Surveillance: The REMOVE Trial

This study, called the REMOVE Trial, is looking at whether a 12-week, home-based exercise program can help slow down prostate cancer progression in men who are at a higher risk of their cancer getting worse. You might be able to join if you are at least 18 years old, have been diagnosed with localized prostate cancer, and are currently on active surveillance (meaning your cancer is being closely watched). You also need to have a higher risk of progression, which could mean you have a certain type of prostate tumor, are obese (BMI of 30 or more), or identify as Black or African American. The study will measure your Prostate-Specific Antigen (PSA) level, a marker for prostate cancer, at the beginning and end of the program to see if the exercise has an effect. The current recruitment status is unclear.

Study design
This is a randomized controlled study with about 68 participants. You would be randomly assigned to either an aerobic high-intensity interval training (HIIT) exercise group or a waitlist control group.
What's involved
Participation in this study is expected to last about 14 weeks. This includes screening, study treatment visits, surveys, and blood tests.
Compensation
Not stated in the trial record.
Follow-up
Your PSA level will be measured at the beginning of the study (Week 1) and after the intervention (Week 14).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05918263

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Recruiting
NAAges 18+InterventionalSupportive care
Fred Hutchinson Cancer Center
~68 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:High-Intensity Interval Training Exercise Program

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prostate-Specific Antigen (PSA) Level
Measured over Baseline (Week 1) and post-intervention (Week 14)

Conditions

Prostate Cancer
Prostatic Neoplasms

Explore related trials

Prostate Carcinoma

Where it's being run

4 sites across 2 states
Massachusetts3
Washington1

Study leadership

  • Dong-Woo Kang, PhD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Dong-Woo Kang, PhD
[email protected]
206-667-5188
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Histologically diagnosed with localized prostate cancer.
Initiating or undergoing active surveillance.
Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American.
No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment.
Ability to understand and willingness to provide informed consent.

Exclusion

Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy.
Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies.
Participating in any (\>0 min/week) high-intensity exercise at the time of recruitment.
Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.
Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).
Patients who are non-English speaking and unable to complete the participant surveys.

What this trial measures

  • Prostate-Specific Antigen (PSA) LevelBaseline (Week 1) and post-intervention (Week 14)

    The primary outcome is the between-group difference in prostate-specific antigen (PSA) levels post-intervention. Analysis of covariance will be used to detect the difference adjusting for baseline values of the outcome and other covariates.